Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with no cure.
• Current treatments, like Riluzole, offer limited efficacy.
• Pathways implicated in neuronal death include oxidative stress, inflammation, and excitotoxicity.

Purpose of the Study:

• To review current therapeutic strategies and research directions for Amyotrophic Lateral Sclerosis (ALS).
• To highlight the role of genetic factors (SOD1, VEGF) and their use in developing animal models.
• To assess the potential of various drug classes and novel therapeutic approaches.

Main Methods:

• Review of existing literature on ALS pathogenesis and drug development.
• Analysis of findings from transgenic mouse models carrying ALS-associated gene mutations (SOD1, VEGF).
• Evaluation of preclinical and clinical trial data for different therapeutic agents.

Main Results:

• Riluzole, the only approved drug, provides only a few months of extended survival.
• Transgenic mouse models have been crucial for testing drugs targeting oxidative damage, inflammation, and trophic support.
• Promising results in mice include gene transfer of VEGF, COX-2 inhibitors, and minocycline.

Conclusions:

• No single drug has proven effective, indicating the complexity of ALS.
• Combination therapies targeting multiple pathways are likely necessary for effective ALS treatment.
• Further research into genetic factors and novel drug combinations is essential for future breakthroughs.